Los puntos clave no están disponibles para este artículo en este momento.
Nivolumab plus chemotherapy did not significantly improve PFS versus chemotherapy in patients with EGFR-mutated metastatic NSCLC previously treated with EGFR TKIs. No new safety signals were identified.
Mok et al. (Mon,) studied this question.